Targeting polymyxin-resistant Gram-negative superbugs: development of novel antimicrobial lipopeptides

针对多粘菌素耐药革兰氏阴性超级细菌：新型抗菌脂肽的开发

• 批准号: nhmrc : 606573
• 负责人: Dr Tony Velkov
• 金额: $ 44.08万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-polymyxin-resistant-antimicrobial-lipopeptides/96841
• 关键词: Targeting; polymyxin; resistant; Gram; negative

Prevalence of resistance to antibiotics among Gram-negative 'superbugs' is a major global medical challenge, which is highlighted by the Bad Bugs, No Drugs campaign of the Infectious Diseases Society of America. There are virtually no new antibiotics in the current drug development pipeline for these dangerous pathogens. In this project, novel lipopeptides will be designed, synthesised and evaluated against these 'superbugs'. Information obtained will be crucial for further drug development.

革兰氏阴性“超级细菌”对抗生素的耐药性普遍存在是一项重大的全球医学挑战，美国传染病学会的“坏细菌，无药物”运动强调了这一点。在目前针对这些危险病原体的药物开发管道中，几乎没有新的抗生素。在这个项目中，新的脂肽将被设计、合成并评估对抗这些“超级细菌”的能力。获得的信息将对进一步的药物开发至关重要。